Effects of Dietary Fat Structure on Blood Lipids in Healthy Australian Adults.

Not Applicable

Completed

• Conditions: Cardiovascular function; Diet and Nutrition - Other diet and nutrition disorders; Cardiovascular - Normal development and function of the cardiovascular system

• Registration Number: ACTRN12616000069459
• Lead Sponsor: CSIRO Food and Nutrition

Brief Summary

In young healthy individuals, palm oil and cocoa butter, both rich in saturated fatty acids, but containing primarily unsaturated fatty acid in the sn-2 position of TAG, did not differ from olive oil with regard to their effects on lipid profiles.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-01-21
• Study Completion: 2016-10-31
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 58

Inclusion Criteria

Males and females aged 20-40 years; BMI 18.5 to less than or equal to 27.5 kg/m2; Understand study and agree to participate; Adhere closely to the prescribed food consumption as per the research protocol

Exclusion Criteria

Abnormal liver function test (elevated alanine transaminase (ALT), aspartate transaminase (AST)), abnormal kidney function test (elevated plasma creatinine); History of chronic disease - type 2 diabetes, heart disease, cancer, atherosclerotic disease, hypertension, stomach ulcers, hypo- or hyper-thyroidism; drug abuse or alcoholism; History of pancreatic insufficiency or other conditions resulting in fat malabsorption - chronic pancreatitis, cystic fibrosis, coeliac disease, crohns disease, gastric bypass surgery, small bowel resection; abnormal thyroid function; History of smoking during 6 months prior to study; On lipid/blood pressure lowering medication; Blood pressure >140/90 mmHg; Hyperlipidemia (elevated blood lipids) (fasting total cholesterol > 6.2 mmol/L, triglycerides > 2.0 mmol/L); Extended absences due to travel or other commitments; Known allergy to the test foods; Pregnancy or breastfeeding; Nutritional supplements that may affect the study outcomes; On any weight-loss programs; Females who are on hormone based contraceptives unless stable for at least 3 months prior to study commencement (no changes in type and dose) and have no intention to change during study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Blood Lipid Profile: Total Cholesterol, LDL-C, HDL-C, TAG, TC:HDL-C ratio)[weeks 0, 2, 6, 8, 12, 14 and 18]

Secondary Outcome Measures

Name	Time	Method
Blood Pressure - automated blood pressure monitor[weeks 0, 2, 6, 8, 12, 14 and 18];Emerging Blood Lipid biomarker - LDL subfractions[weeks 0, 2, 6, 8, 12, 14 and 18];Emerging Blood Lipid biomarkers - apolipoprotein A (apoA), apolipoprotein B (apoB), apoA:apoB ratio[weeks 0, 2, 6, 8, 12, 14 and 18];Emerging Blood Lipid biomarker - Lipoprotein(a)[weeks 0, 2, 6, 8, 12, 14 and 18]